AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial

@article{Lewitt2011AAV2GADGT,
  title={AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial},
  author={P. Lewitt and A. Rezai and M. Leehey and S. Ojemann and A. Feigin and S. Tatter},
  journal={The Lancet Neurology},
  year={2011},
  volume={10},
  pages={309-319}
}
  • P. Lewitt, A. Rezai, +3 authors S. Tatter
  • Published 2011
  • Medicine
  • The Lancet Neurology
    • BACKGROUND Gene transfer of glutamic acid decarboxylase (GAD) and other methods that modulate production of GABA in the subthalamic nucleus improve basal ganglia function in parkinsonism in animal models. We aimed to assess the effect of bilateral delivery of AAV2-GAD in the subthalamic nucleus compared with sham surgery in patients with advanced Parkinson's disease. METHODS Patients aged 30-75 years who had progressive levodopa-responsive Parkinson's disease and an overnight off-medication… CONTINUE READING
    View on Elsevier
    doi.org
    507 Citations
    Highly Influential Citations
    18
    Background Citations
    127
    Methods Citations
    39
    Results Citations
    17

    Supplemental Clinical Trials

    Interventional Clinical Trial
    Study of AAV-GAD Gene Transfer Into the Subthalamic Nucleus for Parkinson's Disease
    The purpose of this study is to determine the safety and efficacy of AAV-GAD gene transfer into the subthalamic nucleus (STN) region of the brain. This study involves the treatment of… Expand
    ConditionsParkinson's Disease
    InterventionGenetic
    Neurologix, Inc.
    Explore Further
    Discover more papers related to the topics discussed in this paper
    507 Citations
    Citation Type

    Citation Type

    Long-term follow-up of a randomized AAV2-GAD gene therapy trial for Parkinson's disease.
    • 32
    [Gene therapy for Parkinson's disease].
    • S. Muramatsu
    • Medicine
    • Rinsho shinkeigaku = Clinical neurology
    • 2012
    • 1
    Parkinson disease: Gene therapy for Parkinson disease shows promise in phase II trial
    • 3
    Of Monkeys and Men: Analysis of the Phase 2 Double-Blind, Sham-Surgery Controlled, Randomized Trial of AAV2-Neurturin Gene Therapy for Parkinson’s Disease
    • 9
    Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial
    • 318
    • PDF
    Gene Therapy for Parkinson’s Disease: Preclinical Evaluation of Optimally Configured TH:CH1 Fusion for Maximal Dopamine Synthesis
    • 2
    GAD Gene Therapy for Parkinson’s Disease
    • 3
    Gene therapy for Parkinson's disease: Disease modification by GDNF family of ligands
    • 32
    Data-driven evolution of neurosurgical gene therapy delivery in Parkinson’s disease
    • 1
    • PDF
    Gene Therapy for Parkinson’s Disease: Still a Hot Topic?
    • 7
    • PDF

    References

    SHOWING 1-10 OF 35 REFERENCES
    Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial
    • 389
    Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial
    • 907
    • PDF
    A Phase I Study of Aromatic L-Amino Acid Decarboxylase Gene Therapy for Parkinson's Disease.
    • 177
    Safety and tolerability of putaminal AADC gene therapy for Parkinson disease
    • 321
    A randomized trial of deep-brain stimulation for Parkinson's disease.
    • 2,080
    • PDF
    Subthalamic Glutamic Acid Decarboxylase Gene Therapy: Changes in Motor Function and Cortical Metabolism
    • M. Emborg, M. Carbon, +10 authors D. Eidelberg
    • Biology, Medicine
    • Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism
    • 2007
    • 117
    Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2–neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial
    • 478
    Subthalamic GAD Gene Therapy in a Parkinson's Disease Rat Model
    • 291
    Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease
    • 169
    • PDF
    Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease.
    • 950
    • PDF